Channel: VJRegenMed clear
| # | Channel | Title | Views | Likes | Cmts | Score | Sentiment | Duration | Transcript | Link |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | VJRegenMed | Developing iPSC-derived MSCs for therapeutic purposes | 188 | 4 | 47.2 | 1:45 | Thank you very much for that question because it's core to what we're doing at the bone therapeutics. It's really bringing in technology, IP and know-how and materials to complement what we already have in MSCs. As I said, we want to take MSCs of different origins and educate them, professionalize them for therapeutic benefits. So we're going to look at MSCs not just from bone marrow, but looking at IPSEs. I mean, the field of IPSE is expanding. Regulatory-wise people are more comfortable. There's IPSE-derived cells in the clinical trial. We aim at delivering MSCs from IPSEs and then educate gene-modify growth factor influence those MSCs into therapeutic cells. Bone therapeutics leading product alloc is already one asset like that. The following assets will go into inflammation and other conditions, really because we know that MSCs can deliver an effect, like for instance on graph versus those disease, but they can't that effect is not ideal. We can optimize it. And the technology we're getting from implant in terms of IPSE sourcing, in terms of epimonogenic MSCs, in terms of gene editing ourselves, will enable us to take the platform of IMSC. I as in use changed IMSC forward to obtain MSC based, Selon gene therapy product professional for therapeutic objective. | ↗ |